Compare AbbVie Inc (ABBV) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? AbbVie Inc trades at $249.02 (market cap $438.19B), while YieldMax MSTR Option Income Strategy ETF trades at $12.46. The key difference: AbbVie Inc pays a 2.79% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | MSTY | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $96.95 |
52-Week Low | $197.38 | $11.55 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $249.94, up 1.59% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats (Q4 2025 to Q2 2026) and a 70.73% buy rating from analysts highlight confidence. Revenue grew to $61.16B in 2025, though net margin dipped to 6.9%, while Skyrizi and Rinvoq drive growth post-Humira patent expiry. A dividend of $1.73 is scheduled for August 2026, supporting income appeal.
Outlook is positive with a $281.33 price target, but risks include high P/E of 70.05, patent cliffs in the 2030s, and regulatory lawsuits. Institutional buying and robust pipeline innovations like ELAHERE® in ovarian cancer offer upside, yet valuation and competitive pressures warrant caution for growth sustainability.
MSTY (YieldMax MSTR Option Income Strategy ETF) trades at $12.82, up 2.31% today, but remains in a significant downtrend with a 67% decline year-to-date. The ETF faces structural challenges as high distribution yields mask substantial NAV erosion, with technical indicators showing neutral momentum amid bearish moving averages. Recent news highlights concerns about the fund returning investor capital as distributions while experiencing deep losses.
The outlook remains challenged by the ETF's structural limitations that cap upside potential while exposing investors to full downside risk. Investment opportunity exists only for sophisticated investors seeking high current income despite principal erosion, while risks include continued NAV decline, tax inefficiency, and dependence on MicroStrategy's volatile performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
